Javier Cervera

Javier Cervera

Auto-generated profile, based on publicly available information

Javier Cervera

Centro de Investigación Príncipe Felipe (CIPF), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII)

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2010 in Protein Science
Verified
Journal Article
Open access
PDF file
IPIsabel Pérez‐Arellano
Isabel Pérez‐Arellano
FCFrancisco Carmona‐Álvarez
Francisco Carmona‐Álvarez
AMAna I. Martínez
Ana I. Martínez
Jesus Rodriguez DiazJesus Rodriguez Diaz
Jesus Rodriguez Diaz
JCJavier Cervera
Javier Cervera
Pyrroline‐5‐carboxylate synthase (P5CS) is a bifunctional enzyme that exhibits glutamate kinase (GK) and γ‐glutamyl phosphate reductase (GPR) activities. The enzyme is highly relevant in humans because it belongs to a combined route for the interconversion of glutamate, ornithine and proline. The deficiency of P5CS activity in humans is associated with a rare, inherited metabolic disease. It is well established that some bacteria and plants accumulate proline in response to osmotic stress. The alignment of P5CSs from different species and analysis of the solved structures of GK and GPR reveal high sequence and structural conservation. The information acquired from different mutant enzymes with increased osmotolerant properties, together with the position of the insertion found in the longer human isoform, permit the delimitation of the regulatory site of GK and P5CS and the proposal of a model of P5CS architecture. Additionally, the GK moiety of the human enzyme has been modeled and the known clinical mutations and polymorphisms have been mapped.

4 September 2007 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
IPIsabel Pérez‐Arellano
Isabel Pérez‐Arellano
JGJosé Gallego
José Gallego
JCJavier Cervera
Javier Cervera
The pseudouridine synthase and archaeosine transglycosylase (PUA) domain is a compact and highly conserved RNA‐binding motif that is widespread among diverse types of proteins from the three kingdoms of life. Its three‐dimensional architecture is well established, and the structures of several PUA–RNA complexes reveal a common RNA recognition surface, but also some versatility in the way in which the motif binds to RNA. The PUA domain is often part of RNA modification enzymes and ribonucleoproteins, but it has also been unexpectedly found fused to enzymes involved in proline biosynthesis, where it plays an unknown role. The functional impact of the domain varies with the protein studied, ranging from minor to essential effects. PUA motifs are involved in dyskeratosis congenita and cancer, pointing to links between RNA metabolism and human diseases.

18 May 2010 in Human Mutation
Verified
Journal Article
Open access
PDF file
Satu PekkalaSatu Pekkala
Satu Pekkala
AMAna I. Martínez
Ana I. Martínez
BBBelén Barcelona
Belén Barcelona
IYIgor Yefimenko
Igor Yefimenko
UFUlrich Finckh
Ulrich Finckh
JCJavier Cervera
Javier Cervera
Carbamoyl-phosphate synthetase I (CPS1) deficiency (CPS1D), a recessively inherited urea cycle error due to CPS1 gene mutations, causes life-threatening hyperammonemia. The disease-causing potential of missense mutations in CPS1 deficiency can be ascertained with the recombinant CPS1 expression and purification system reported here, which uses baculovirus and insect cells. We study with this system the effects of nine clinical mutations and one polymorphism on CPS1 solubility, stability, activity, and kinetic parameters for NAG. Five of the mutations (p.T471N, p.Q678P, p.P774L, p.R1453Q, and p.R1453W) are first reported here, in three severe CPS1D patients. p.P774L, p.R1453Q, and p.R1453W inactivate CPS1, p.T471N and p.Y1491H greatly decrease the apparent affinity for NAG, p.Q678P hampers correct enzyme folding, and p.S123F, p.H337R, and p.P1411L modestly decrease activity. p.G1376S is confirmed a trivial polymorphism. The effects of the C-terminal domain mutations are rationalized in the light of this domain crystal structure, including the NAG site structure [Pekkala et al. Biochem J 424:211–220]. The agreement of clinical observations and in vitro findings, and the possibility to identify CPS1D patients who might benefit from specific treatment with NAG analogues because they exhibit reduced affinity for NAG highlight the value of this novel CPS1 expression/purification system. Hum Mutat 31:1–8, 2010.

11 November 2009 in Biochemical Journal
Verified
Journal Article
Closed access
Satu PekkalaSatu Pekkala
Satu Pekkala
AMAna I. Martínez
Ana I. Martínez
BBBelén Barcelona
Belén Barcelona
JGJosé Gallego
José Gallego
EBElena Bendala
Elena Bendala
JCJavier Cervera
Javier Cervera
NAG (N-acetyl-L-glutamate), the essential allosteric activator of the first urea cycle enzyme, CPSI (carbamoyl phosphate synthetase I), is a key regulator of this crucial cycle for ammonia detoxification in animals (including humans). Automated cavity searching and flexible docking have allowed identification of the NAG site in the crystal structure of human CPSI C-terminal domain. The site, a pocket lined by invariant residues and located between the central β-sheet and two α-helices, opens at the β-sheet C-edge and is roofed by a three-residue lid. It can tightly accommodate one extended NAG molecule having the δ-COO− at the pocket entry, the α-COO− and acetamido groups tightly hydrogen bonded to the pocket, and the terminal methyl of the acetamido substituent surrounded by hydrophobic residues. This binding mode is supported by the observation of reduced NAG affinity upon mutation of NAG-interacting residues of CPSI (recombinantly expressed using baculovirus/insect cells); by the fine-mapping of the N-chloroacetyl-L-glutamate photoaffinity labelling site of CPSI; and by previously established structure–activity relationships for NAG analogues. The location of the NAG site is identical to that of the weak bacterial CPS activator IMP (inosine monophosphate) in Escherichia coli CPS, indicating a common origin for these sites and excluding any relatedness to the binding site of the other bacterial CPS activator, ornithine. Our findings open the way to the identification of CPSI deficiency patients carrying NAG site mutations, and to the possibility of tailoring the activator to fit a given NAG site mutation, as exemplified here with N-acetyl-L(±)-β-phenylglutamate for the W1410K CPSI mutation.

11 June 2010 in Extremophiles
Verified
Journal Article
Closed access
PDF file
IPIsabel Pérez-Arellano
Isabel Pérez-Arellano
JCJavier Cervera
Javier Cervera